TAK1-inhibitors did not reduce disease burden in a Vκ*MYC model of multiple myeloma

OBJECTIVE: Multiple myeloma is a haematological malignancy characterized by proliferation of monoclonal plasma cells in the bone marrow. Development of resistance and minimal residual disease remain challenging in the treatment of multiple myeloma. Transforming growth factor-β activated kinase 1 (TA...

Descripción completa

Detalles Bibliográficos
Autores principales: Håland, Erling, Moen, Ingrid Nyhus, Vandsemb, Esten N., Starheim, Kristian K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Note
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701378/
https://www.ncbi.nlm.nih.gov/pubmed/36435864
http://dx.doi.org/10.1186/s13104-022-06237-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701378/
https://www.ncbi.nlm.nih.gov/pubmed/36435864
http://dx.doi.org/10.1186/s13104-022-06237-3

Ejemplares similares